Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Trial Profile

A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Jun 2019 Results assessing molecular circulating tumor DNA response to identify long-term survival from NCT01693562, NCT02087423 and NCT02261220 trials presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results assessing longitudinal tumor size and neutrophil to lymphocyte ratio from NCT02087423 and NCT01693562, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Apr 2019 Results of deep learning analysis of circulating tumor DNA using blood samples from 4 nonrandomized phase 2 trials (NCT01693562, NCT02000947, NCT02261220 and NCT02087423) presented at the 110th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top